Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Entera Bio Ltd. ENTX
$0.89
-$0.01 (-1.12%)
На 18:01, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
25928910.00000000
-
week52high
2.57
-
week52low
0.47
-
Revenue
134000
-
P/E TTM
-2
-
Beta
1.84203400
-
EPS
-0.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 19 июл 2022 г. |
| B. Riley Securities | Buy | 16 июн 2021 г. | |
| Aegis Capital | Buy | 22 мар 2021 г. | |
| Maxim Group | Buy | 03 авг 2018 г. | |
| HC Wainwright & Co. | Buy | 06 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| GARCEAU ROGER | A | 89041 | 89041 | 02 янв 2023 г. |
| Mayron Ron | A | 89041 | 89041 | 02 янв 2023 г. |
| LIEBERMAN GERALD M | A | 89041 | 89041 | 02 янв 2023 г. |
| OSTROV GERALD M | A | 89041 | 89041 | 02 янв 2023 г. |
| Ellis Sean | A | 89041 | 89041 | 02 янв 2023 г. |
| Malca Yonatan | A | 89041 | 89041 | 02 янв 2023 г. |
| LIEBERMAN GERALD M | A | 6200 | 4000 | 14 ноя 2022 г. |
| LIEBERMAN GERALD M | A | 194209 | 34000 | 14 ноя 2022 г. |
| Yaacov-Garbeli Dana | A | 56580 | 26580 | 14 ноя 2022 г. |
| Yaacov-Garbeli Dana | A | 30000 | 30000 | 11 ноя 2022 г. |
Новостная лента
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
05 мая 2023 г. в 18:57
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12.
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
31 мар 2023 г. в 18:22
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.
Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know
Zacks Investment Research
02 февр 2023 г. в 19:34
Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.
Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know
Zacks Investment Research
25 янв 2023 г. в 19:33
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.
New Strong Buy Stocks for December 29th
Zacks Investment Research
29 дек 2022 г. в 09:47
SPNS, CRS, DHT, DCBO and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on December 29, 2022.